Orchestra BioMed Holdings Inc. (OBIO) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Orchestra BioMed Holdings Inc. (NASDAQ: OBIO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $5.91 (-2.96% 1D, market cap $366.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, OBIO ranks #633 in composite RQD confidence.
Within the Health Care sector (Medicinal Chemicals and Botanical Products), OBIO carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, TLRY (Tilray Brands Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -3.9%, cap $390.2M) and SNDL (SNDL Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $316.3M). Among the 5-stock peer group, USNA leads on earnings multiple (24.6x) while USNA leads on capital efficiency (7.9% ROIC).
Per OBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001814114), Orchestra BioMed Holdings Inc. generated $33.5M in revenue (+1169.2% YoY), -$52.7M in net income, and -$49.5M in free cash flow against $114.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±11.7% realized swing band)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While OBIO currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.72) and Max Pain ($6.21) forces dealer call-delta covering toward $6.83.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Orchestra BioMed Holdings Inc. (OBIO) dropped -2.96% to $5.91, trading at 81% of its 52-week range ($3.46 – $6.5). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance Australia report covering Orchestra BioMed Holdings Inc. (OBIO) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Orchestra BioMed Holdings Inc. (OBIO) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Orchestra BioMed Holdings Inc. (OBIO) market action, institutional positioning, and fundamental catalysts.
Investing.com Canada report covering Orchestra BioMed Holdings Inc. (OBIO) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Orchestra BioMed Holdings Inc. (OBIO) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Orchestra BioMed Holdings Inc. (OBIO) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Orchestra BioMed Holdings Inc. (OBIO) market action, institutional positioning, and fundamental catalysts.
Investing.com India report covering Orchestra BioMed Holdings Inc. (OBIO) market action, institutional positioning, and fundamental catalysts.
Presentation will highlight Virtue SAB’s fundamentally different approach of infusing a large liquid volume of proprietary extended-release SirolimusEFR™ directly into and throughout the vessel wall.Virtue SAB’s mechanis
Gainers Pomdoctor (NASDAQ:POM) shares rose 25.6% to $1.47 during Friday's after-market session. The market value of their outstanding shares is at $8.3 million. GeneDx Holdings (NASDAQ:WGS) shares rose 8.72% to
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on OBIO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for OBIO. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Orchestra BioMed Holdings Inc. (OBIO) ranks #633 by composite RQD confidence (36/100, grade D-) and #495 by equity capitalization ($366.0M). Within this direct 5-issuer industry benchmark cohort, USNA leads on earnings valuation at 24.6x trailing P/E, while USNA leads on capital efficiency and profitability with 7.9% ROIC and 78.3% gross margin. USNA currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with OBIO at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| OBIO
ACTIVE
Orchestra BioMed Holdings Inc. | D- | 36/100 | — | 96.0% | -35.0% | -2.96% | $366.0M | Benchmark Subject |
| TLRY Tilray Brands Inc. | E | 20/100 | — | 28.4% | -3.9% | -4.17% | $390.2M | /tlry-vs-obio → |
| SNDL SNDL Inc. | D | 48/100 | — | — | — | -4.61% | $316.3M | /sndl-vs-obio → |
| CGC Canopy Growth Corporation | D- | 41/100 | — | — | — | -3.33% | $285.6M | /cgc-vs-obio → |
| USNA USANA Health Sciences Inc. | D | 50/100 | 24.6x | 78.3% | 7.9% | -0.21% | $265.0M | /usna-vs-obio → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Orchestra BioMed Holdings Inc. (OBIO) reported GAAP revenue of $33.5M (+1169.2% vs. FY2024 revenue of $2.6M , and +1113.1% cumulative change since FY2023) , GAAP net income of -$52.7M, operating cash flow of -$49.0M, and free cash flow of -$49.5M (+2.7% YoY). On the balance sheet, OBIO closed FY2025 with $114.9M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $33.5M | -$52.7M | -$49.0M | -$49.5M | $114.9M | — |
| FY2024 (FY) | 2024-12-31 | $2.6M | -$61.0M | -$50.6M | -$50.8M | $76.2M | — |
| FY2023 (FY) | 2023-12-31 | $2.8M | -$49.1M | -$46.1M | -$46.1M | — | — |
As of 2026-11-02, Orchestra BioMed Holdings Inc. (NASDAQ: OBIO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $5.91 (-2.96% 1D, market cap $366.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, OBIO ranks #633 in composite RQD confidence.
Within the Health Care sector (Medicinal Chemicals and Botanical Products), OBIO carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, TLRY (Tilray Brands Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -3.9%, cap $390.2M) and SNDL (SNDL Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $316.3M). Among the 5-stock peer group, USNA leads on earnings multiple (24.6x) while USNA leads on capital efficiency (7.9% ROIC).
Per OBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001814114), Orchestra BioMed Holdings Inc. generated $33.5M in revenue (+1169.2% YoY), -$52.7M in net income, and -$49.5M in free cash flow against $114.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
OBIO last traded at $5.91 (-2.96% on volume of 232,440 shares), positioning the stock +3.32% above its 50-day simple moving average ($5.72) and +30.18% above its 200-day simple moving average ($4.54). Across its 52-week range of $3.46 to $6.50, OBIO sits at the 80.6% percentile with a 14-day RSI of 57.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.7% ($5.22 to $6.60).
Why OBIO Stock dropped -2.96% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, OBIO carries an RQD Score of 36 out of 100, graded D-, with a verdict label of "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are scored as follows:
For a prospective investor evaluating the stock today, the upside case rests on the institutional flow pillar and the 96% gross margin reported in the market data; the source does not show that margin converting into operating profit. The valuation tradeoff is stark: the company reports an operating margin of -60% and a net margin of -60%, so conventional earnings multiples cannot be computed from the source. Ripple risk is concentrated in the balance sheet and cash-flow pillars, since sustained negative FCF would pressure the cash balance over time. This brief is educational and is not personalized financial advice.
Orchestra BioMed Holdings Inc. (OBIO) is a NASDAQ-listed issuer in the Health Care sector, classified under the Medicinal Chemicals and Botanical Products industry, per the company profile. The profile does not describe its products, customers, or revenue model. Per the SEC financials, the company reported revenue of $33.5M for FY 2025, up from $2.6M in FY 2024 and $2.8M in FY 2023. The source data does not explain how this revenue is generated.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $33.5M | $-51.8M | $-52.7M | N/A | $-49.5M | $34.7M | N/A |
| FY 2024 | $2.6M | $-64.3M | $-61.0M | N/A | $-50.8M | $22.3M | N/A |
| FY 2023 | $2.8M | $-51.5M | $-49.1M | N/A | $-46.1M | N/A | N/A |
Per the SEC financials, the company has reported operating losses in each period shown. Per the market data, gross margin is 96%, operating margin is -60%, net margin is -60%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 5/9, with Debt/Equity of 0.5. Reported cash rose to $34.7M in FY 2025 from $22.3M in FY 2024, while free cash flow remained negative in every period shown.
Per the recent news and catalysts feed, six items were reported. Five are tagged as market wire items and rated YELLOW. One item, a Stock Traders Daily report, is tagged RISK WATCH and rated RED. The feed's summaries are generic and do not contain substantive detail beyond headline content.
Headline items include: a Seeking Alpha report titled "Orchestra BioMed Has A Clearer Trial Timeline But A Demanding Valuation"; a TradingView report noting a Chardan Capital Buy rating with a $20 price target; an Investing.com Canada report on H.C. Wainwright reiterating its rating on trial enrollment; and a Stock Titan report describing a balloon designed to deliver liquid medicine into artery walls, to be presented at a heart meeting. The RISK WATCH item is a Stock Traders Daily piece on risk zones for the stock.
Per the butterfly supply-chain graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data. The only sector-level context provided is the Health Care sector classification and beta of 1.0 per the market data.
Real-time company headlines, analyst actions, and sector developments for Orchestra BioMed Holdings Inc. (OBIO) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance Australia report covering Orchestra BioMed Holdings Inc. (OBIO) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Orchestra BioMed Holdings Inc. (OBIO) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Orchestra BioMed Holdings Inc. (OBIO) market action, institutional positioning, and fundamental catalysts.
Investing.com Canada report covering Orchestra BioMed Holdings Inc. (OBIO) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Orchestra BioMed Holdings Inc. (OBIO) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Orchestra BioMed Holdings Inc. (OBIO) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Orchestra BioMed Holdings Inc. (OBIO) market action, institutional positioning, and fundamental catalysts.
Investing.com India report covering Orchestra BioMed Holdings Inc. (OBIO) market action, institutional positioning, and fundamental catalysts.
Welcome to the OBIO (Orchestra BioMed Holdings Inc.) Roar Pit. Current RQD Composite is 36/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Medicinal Chemicals and Botanical Products. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on OBIO, but look at what you are paying: current EV/EBITDA multiples with 96.0% gross margins. Unless Orchestra BioMed Holdings Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on OBIO, the market is fixating on short-term headline noise in Medicinal Chemicals and Botanical Products and ignoring the balance sheet and cash flow trajectory. At $6.09 (52-wk range $3.46 - $6.50), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).